CD19 and acute lymphoblastic leukemia: The tri-specific products were also tested in models of CD19-negative relapse and CRISPR-mediated CD19 knockouts, demonstrating effective cytokine production and enhanced killing of CD19-negative ALL cells, suggesting lessened incidence of antigenic-escape [33].